ATYR

aTYR PHARMA INC ATYR

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,883 of 2,925

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Net income

$-10.31M

Quarter to Jun 30

Free cash flow

$-9.42M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$23.18M total
FEDERATED HERMES, INC.
$5.08M-19.0%
VANGUARD CAPITAL MANAGEMENT LLC
$2.27M-0.1%
GSA CAPITAL PARTNERS LLP
$2.06M+105.1%
AQR CAPITAL MANAGEMENT LLC
$1.56M+426.3%
FMR LLC
$1.47M-83.2%
BlackRock, Inc.
$1.09M-71.6%
Kalehua Capital Management LLC
$1.07MNew
JANE STREET GROUP, LLC
$1.03M+3448.9%
UBS Group AG
$914.1K-60.4%
MORGAN STANLEY
$801.9K+9.6%
TWO SIGMA INVESTMENTS, LP
$743.1K+8.8%
CITADEL ADVISORS LLC
$741.3K+2521.9%
GEODE CAPITAL MANAGEMENT, LLC
$702.7K-50.7%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$445.8K-13.8%
MILLENNIUM MANAGEMENT LLC
$391.5K-60.0%
GOLDMAN SACHS GROUP INC
$382.7K+126.4%
VANGUARD FIDUCIARY TRUST CO
$343.9K-11.6%
STATE STREET CORP
$295.4K-71.8%
MARSHALL WACE, LLP
$220.9K+166.5%
XTX Topco Ltd
$135.3K+103.4%
NORTHERN TRUST CORP
$131.4K-69.0%
BANK OF AMERICA CORP /DE/
$123.7K-31.7%
RENAISSANCE TECHNOLOGIES LLC
$98.6K+307.7%
JPMORGAN CHASE & CO
$85.3K+258.8%
GROUP ONE TRADING, L.P.
$82.9K-24.5%
See all 90 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ATYR

Earnings Per Share

13fpro.ai/company/ATYR

Loading ratio trend…

ATYR key financials by period

Reported revenue, net income and operating margin by fiscal year, from aTYR PHARMA INC's annual filings on SEC EDGAR.

aTYR PHARMA INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$190.0K$-74.1M—
FY 2024$235.0K$-64.0M—
FY 2023$353.0K$-50.4M—
FY 2022$10.4M$-45.3M—
FY 2020$10.5M$-16.2M-152.2%
FY 2019$422.0K$-16.2M—
Source: ATYR filings on SEC EDGAR →

ATYR insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About aTYR PHARMA INC (ATYR): stock profile, AI score and financials

aTYR PHARMA INC (ATYR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATYR at 8.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,883 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), aTYR PHARMA INC reports net income of $-10.3M, free cash flow of $-9.4M. Top institutional holders of ATYR by reported 13-F value include FEDERATED HERMES, VANGUARD CAPITAL MANAGEMENT, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. ATYR trades on the Nasdaq exchange and files with the SEC under CIK 1339970. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATYR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for aTYR PHARMA INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1339970 →